Stem cell transplantation for chronic myeloid leukemia in children.
暂无分享,去创建一个
S. Iacobelli | R. Brand | G. Dini | M. Aljurf | D. Niederwieser | F. Locatelli | I. Roberts | W. Arcese | J. Apperley | A. van Biezen | D. Niethammer | J. Vossen | A. Devergie | K. Cwynarski
[1] C. Craddock,et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. , 2002, Blood.
[2] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[3] J. Wagner,et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. , 2001, The American journal of medicine.
[4] C. Craddock,et al. Cytomegalovirus seropositivity adversely influences outcome after T‐depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft‐versus‐host disease prophylaxis , 2001, British journal of haematology.
[5] C. Craddock,et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia , 2000 .
[6] V. Kuenen-Boumeester,et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. , 2000, Blood.
[7] A. Nademanee,et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. , 2000, Blood.
[8] J. Klein,et al. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. , 2000, Blood.
[9] W. Siegert,et al. Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure , 1999 .
[10] S. Woolf,et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. , 1999, Blood.
[11] Anajane G. Smith,et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.
[12] J Hermans,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.
[13] K. Sullivan,et al. Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase , 1998 .
[14] Lamparelli,et al. Unrelated donor marrow transplantation for chronic myelogenous leukaemia , 1998, British journal of haematology.
[15] C Anasetti,et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.
[16] H. Heimpel,et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. , 1998, Blood.
[17] G. Gahrton,et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation , 1997, Bone Marrow Transplantation.
[18] D. Srivastava,et al. Outcomes of transplantation with matched-sibling and unrelateddonor bone marrow in children with leukaemia , 1997, The Lancet.
[19] M. Labopin,et al. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching , 1997, Bone Marrow Transplantation.
[20] J. Klein,et al. IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE , 1997, British journal of haematology.
[21] A. Gratwohl,et al. Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) , 1997, Bone Marrow Transplantation.
[22] J P Klein,et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] F. Locatelli,et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children: experience of eight European Countries. The EBMT Paediatric Diseases Working Party. , 1996, Bone marrow transplantation.
[24] G. Hale,et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission , 1996, British journal of haematology.
[25] H. Kantarjian,et al. Treatment of Chronic Myelogenous Leukemia: Current Status and Investigational Options , 1996 .
[26] P. Ljungman,et al. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. , 1995, Bone marrow transplantation.
[27] M. Hessner,et al. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. , 1995, Blood.
[28] J. Goldman,et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. , 1995, Blood.
[29] K. Sullivan,et al. Unrelated donor marrow transplantation in children. , 1995, Blood.
[30] S. Mackinnon,et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.
[31] G. Longton,et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. , 1995, Blood.
[32] G. Dini,et al. Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. , 1995, Blood.
[33] A. Elmaagacli,et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. , 1995, Blood.
[34] D. Blaise,et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). , 1995, Blood.
[35] H. Deeg,et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. , 1994, Blood.
[36] V. Vitale,et al. Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables (Sokal score). , 1993, Bone marrow transplantation.
[37] N. Ramsay,et al. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] J. Kersey,et al. RISK FACTORS FOR ACUTE GRAFT‐VERSUS‐HOST DISEASE IN HISTOCOMPATIBLE DONOR BONE MARROW TRANSPLANTATION , 1991, Transplantation.
[39] A. J. Altman,et al. Chronic leukemias of childhood. , 1988, Pediatric clinics of North America.
[40] K B McCredie,et al. Characteristics of accelerated disease in chronic myelogenous leukemia , 1988, Cancer.
[41] R. Marcus,et al. Bone marrow transplantation for patients with chronic myeloid leukemia. , 1986, The New England journal of medicine.
[42] A. Rimm,et al. ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA , 1984, The Lancet.
[43] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.
[44] K. Sullivan,et al. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. , 1998, Blood.
[45] J Hermans,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1998, Lancet.
[46] H. Kantarjian,et al. Treatment of myelogenous leukemia: current status and investigational options. , 1996, Blood.
[47] M. Horowitz,et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. , 1994, Blood.
[48] D. Weisdorf,et al. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation. , 1994, Bone marrow transplantation.
[49] M. Horowitz,et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. , 1993, Blood.
[50] F. Oski,et al. Hematology of Infancy and Childhood , 1974 .